secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2023-04-11T23:59:59+00:00
Accession:  0001493152-23-011805
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo furnishes Part B final data charts for ANEB-001 Phase 2 trial, consistent with prior results
--------------------------------------------------------------------------------

- Exhibit 99.1 contains graphical charts of Part B final data from Phase 2 trial of ANEB-001 for acute cannabinoid intoxication.
- Data shown is consistent with results reported in the March 28, 2023 Form 8-K.
- Trial was randomized, double-blind, placebo-controlled in healthy volunteers challenged with oral delta-9-THC.
- No new clinical findings or updated guidance are provided in this filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315223011805/0001493152-23-011805-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315223011805/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-011805

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer